Clinical Scorecard: Effectiveness of Intravenous Parecoxib in Reducing the Incidence of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis: Results from a Randomized Controlled Study
PEP involves pancreatic-type abdominal pain with elevated pancreatic enzymes post-ERCP; NSAIDs inhibit phospholipase A2, cyclooxygenase, and neutrophil–endothelial interactions to reduce inflammation
Target Population
Patients aged 18–75 years undergoing first therapeutic ERCP with naïve papilla, ASA physical status I or II
Care Setting
Hospital setting during and after ERCP procedure
Key Highlights
PEP incidence ranges from 3.5% to 14.7% with mortality up to 0.7%, defined by new/worsening pancreatic pain and ≥3-fold increase in serum amylase/lipase within 24 hours post-ERCP
Rectal NSAIDs (indomethacin or diclofenac) effectively reduce PEP incidence, but rectal formulations are unavailable in some regions like Thailand
Intravenous parecoxib, a selective COX-2 inhibitor with rapid onset, may be an effective alternative for PEP prevention
Guideline-Based Recommendations
Diagnosis
PEP diagnosis requires new or worsening pancreatic-type abdominal pain plus ≥3-fold increase in serum amylase or lipase within 24 hours after ERCP requiring hospitalization
Post-ERCP hyperamylasemia is defined as ≥3-fold increase in serum amylase without clinical pancreatitis
Post-ERCP abdominal pain is defined as VAS >3/10 at 4 and 24 hours post-ERCP without meeting PEP criteria
Management
Use of rectal NSAIDs (indomethacin 100 mg or diclofenac 100 mg) is recommended for PEP prevention
Aggressive hydration with lactated Ringer’s solution and other pharmacologic agents (somatostatin, glyceryl trinitrate, protease inhibitors) may be used
Intravenous parecoxib 40 mg administered preoperatively may reduce PEP incidence and post-ERCP abdominal pain
Monitoring & Follow-up
Monitor serum amylase or lipase levels within 24 hours post-ERCP
Assess abdominal pain severity using visual analog scale at 4 and 24 hours post-procedure
Observe for signs of PEP requiring hospitalization or prolonged stay
Risks
Contraindications to NSAIDs or COX-2 inhibitors include allergies, coagulopathy, severe heart failure, advanced kidney disease, decompensated cirrhosis, and recent pancreatitis
Potential adverse effects of NSAIDs should be considered, though intravenous parecoxib has shown no serious adverse events in prior studies
Patient & Prescribing Data
Adults aged 18–75 undergoing first therapeutic ERCP with naïve papilla, ASA I or II, excluding those with significant comorbidities or contraindications
Intravenous parecoxib offers rapid analgesic onset and may be a viable alternative to rectal NSAIDs for PEP prevention, especially where rectal formulations are unavailable
Clinical Best Practices
Screen patients for PEP risk factors including female sex, history of pancreatitis, suspected sphincter of Oddi dysfunction, and age <35 with normal bilirubin
Administer intravenous parecoxib 40 mg pre-ERCP in eligible patients to reduce PEP incidence
Ensure double-blind randomization and standardized hydration protocols during ERCP
Monitor patients closely for abdominal pain and enzyme elevation post-ERCP to promptly identify PEP
Avoid NSAIDs in patients with contraindications such as coagulopathy, severe cardiac or renal disease, or allergies
